Becaplermin

{{Infobox drug

| Verifiedfields = changed

| verifiedrevid = 458285090

| image =

| alt =

| caption =

| tradename = Regranex

| Drugs.com = {{drugs.com|CDI|becaplermin}}

| MedlinePlus = a699049

| pregnancy_AU =

| pregnancy_category =

| routes_of_administration = Topical

| ATC_prefix = A01

| ATC_suffix = AD08

| ATC_supplemental = , {{ATC|D03|AX06}}

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US = Rx-only

| legal_US_comment = {{cite web | title=Regranex- becaplermin gel | website=DailyMed | date=11 December 2023 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd2c7d21-7b07-4ab3-8983-816ab3223771 | access-date=26 October 2024}}

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 165101-51-9

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank = DB00102

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 1B56C968OA

| ChEMBL_Ref = {{ebicite|changed|EBI}}

| ChEMBL = 1201556

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| IUPAC_name =

| chemical_formula =

| molecular_weight =

}}

Becaplermin, sold under the brand name Regranex, is a cicatrizant, available as a topical gel. Regranex is a human platelet-derived growth factor indicated along with good wound care for the treatment of lower extremity diabetic neuropathic ulcers. It is also known as "platelet-derived growth factor BB".

Medical uses

Becaplermin is used for the treatment of diabetic foot ulcers.{{cite journal | vauthors = Nagai MK, Embil JM | title = Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers | journal = Expert Opinion on Biological Therapy | volume = 2 | issue = 2 | pages = 211–8 | date = February 2002 | pmid = 11849120 | doi = 10.1517/14712598.2.2.211 | s2cid = 28408255 }} Studies of becaplermin showed that when used with good wound care, complete healing significantly increased and the ulcers healed on average 6 weeks faster.{{cite journal | vauthors = Wieman TJ, Smiell JM, Su Y | title = Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study | journal = Diabetes Care | volume = 21 | issue = 5 | pages = 822–7 | date = May 1998 | pmid = 9589248 | doi = 10.2337/diacare.21.5.822 | s2cid = 20595962 }} Pharmacoeconomic studies reinforce the cost effectiveness of becaplermin as an adjunct to good wound care.{{cite journal | vauthors = Persson U, Willis M, Odegaard K, Apelqvist J | title = The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data | journal = Value in Health | volume = 3 | pages = 39–46 | date = 2000 | issue = Suppl 1 | pmid = 16464208 | doi = 10.1046/j.1524-4733.2000.36027.x | doi-access = free }}

The amount of becaplermin to be applied will vary depending upon the size of the ulcer area. Becaplermin should be stored in the refrigerator. Analysis of healing human wounds showed that PDGF-BB induces fibroblast proliferation and differentiation and was found to increase healing in patients with decreased healing capacity, such as people living with diabetes.Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283-1316.

Contraindications

Becaplermin must not be used at the site of a skin cancer.{{Drugs.com|pro|regranex}} for Regranex.

Adverse effects

The most common side effects in clinical studies were erythematous rashes.

References

Category:Dermatologic drugs